Daewon Pharm Acquires Integrated International Certification for Anti-Bribery and Compliance Management Systems

Simultaneous Certification of ISO 37001 and ISO 37301

Daewon Pharm has obtained an international certification that integrates its anti-bribery and compliance management systems.

On June 30, Daewon Pharm announced that it has acquired integrated certification for the Anti-Bribery Management System (ISO 37001) and the Compliance Management System (ISO 37301).

From the left, Seung-Yeol Baek, Vice Chairman of Daewon Pharmaceutical, Myung-Ok Kim, Deputy Director of Korea Compliance Advancement Institute, and In-Hwan Baek, President of Daewon Pharmaceutical. Daewon Pharmaceutical

ISO 37001 is an international standard for preventing and managing bribery risks within an organization, while ISO 37301 is a management system for ensuring compliance with laws and regulations. Operating both certifications in an integrated manner enables efficient prevention of bribery and management of compliance systems.

Daewon Pharm has maintained and improved its anti-bribery management system since obtaining ISO 37001 certification in 2018. In response to the increasingly stringent regulatory environment in the pharmaceutical industry, the company sought to obtain additional ISO 37301 certification starting late last year, and has since established, reviewed, and enhanced its enterprise-wide management system.

Seung-Yeol Baek, Vice Chairman of Daewon Pharm, stated, "Based on the integrated ISO 37001 and 37301 certifications, we will continuously conduct post-management and internal inspections to establish a culture of transparent management."

This content was produced with the assistance of AI translation services.